



Cost effectiveness of PD-L1 testing in non-small cell lung cancer (NSCLC) using IVDs vs. LDTs¹



Key takeaways from a 2022 academic study published in partnership with UK NEQAS, NordiQC and Roche Diagnostics, comparing the cost effectiveness of PD-L1 testing with in vitro diagnostics (IVDs) versus lab-developed tests (LDTs) using the German healthcare system as a model

Accuracy

LDTs could lead to a
20%
greater chance
of misdiagnosis



Total effectiveness



Approximately
1 in 4
patients could **receive incorrect treatment**
based on LDT results

Cost vs. benefit

IVD testing has **minimal impact to overall diagnostic cost**, yet could lead to a **19% increase in successful diagnosis and treatment**

Patient outcomes



Cost



IVD testing is substantially more effective

for aligning PD-L1-positive NSCLC patients with immunotherapy - leading to **improved outcomes** and a **reduction in overall healthcare costs** associated with disease progression, management of adverse events, and end of life care.